Latest News and Press Releases

PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...

PRESS RELEASE NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Aarhus, Denmark, 1 June 2021 – NMD Pharma A/S,...

PRESS RELEASE NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Aarhus, Denmark, 1 June 2021 – NMD Pharma A/S,...

NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth Aarhus, Denmark, 30 November 2020 – NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for...

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company...

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company...

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...